For laboratory and research use only. Not for human consumption.
Industry News5 min read

Berobenatide: Pfizer's Monthly GLP-1 Gets $1.5B in Backing

Blackstone Life Sciences will fund up to $1.5 billion of Pfizer's monthly GLP-1 candidate berobenatide through 2028. Here is what the deal says, what the Phase 2b data shows, and what is still unknown.

By Peptibase Teamโ€ขNovember 13, 2026
Share:
Berobenatide: Pfizer's Monthly GLP-1 Gets $1.5B in Backing

A Private Equity Check for a Monthly GLP-1

On Wednesday, November 11, 2026, Pfizer announced a funding deal that tells you a lot about where the obesity drug race is heading. Blackstone Life Sciences will cover up to $1.5 billion of development costs for berobenatide, Pfizer's once-monthly GLP-1 receptor agonist, through 2028.

If you follow the GLP-1 family at all, you already know the pattern: weekly shots from the big two, a pill, and now everyone chasing "less often." Berobenatide is Pfizer's bet on the monthly slot. Let's look at what the deal actually says, what the trial data actually shows, and what is still blank. ๐Ÿ’‰

What the Deal Says (and Does Not Say)

Per PharmExec's coverage of the Pfizer press release, Blackstone becomes eligible for milestone payments tied to two things: U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and certain commercial sales milestones after launch.

Two details matter here:

  • Blackstone does not get ownership. PharmExec quotes the release: "Blackstone does not acquire any rights or ownership in berobenatide." Pfizer keeps operational control and development decisions.
  • The milestone amounts were not disclosed. BioSpace reports that BMO said so, and that Leerink expects payments to be spread over the term and rise over time.

So this is not Pfizer selling the drug. It is Pfizer borrowing against its future success, with an investor getting paid only if the drug gets approved and sells.

Why Pfizer Wants This Money

BioSpace notes that berobenatide came to Pfizer through its $10 billion Metsera acquisition the year before. That is a big purchase, and Pfizer now has a long list of trials to pay for.

The BioSpace piece also quotes BMO: "We like the deal structure, particularly given where Pfizer sits in its upcoming LOE cycle." LOE means loss of exclusivity, the point where a blockbuster loses patent protection. Leerink, per the same article, points to the Eliquis patent cliff that begins in April 2028.

Translation: Pfizer needs a new growth engine, obesity is the obvious place to build one, and it would rather not drain its own cash to get there. That is a business story, not a science story. Keep that in mind when you read the headline number.

The Trial Data So Far

Here is the part that matters for anyone researching this class of compounds. Pfizer's Phase 2b program is called VESPER, and the numbers need careful reading.

In the VESPER-1 extension, participants who moved from placebo to 2.4 mg weekly berobenatide reached a non-placebo-adjusted weight loss of 15.9%, with no plateau observed at 32 weeks on the drug (that is week 60 of the overall study). According to the release as reported by MarketScreener, this is an exploratory extension, and the figure is not placebo-adjusted.

That caveat is not a footnote. A non-placebo-adjusted number from an exploratory extension is not the same thing as a headline Phase 3 result. You cannot lay it next to a pivotal trial figure and declare a winner. Anyone doing that is selling something.

On tolerability, the release describes "low gastrointestinal (GI) adverse events and discontinuations despite rapid dose escalation and no allowed step-down." That is the company's own framing, and it is a genuinely interesting claim, since GI side effects during dose escalation are the main reason people quit GLP-1 therapy. But it comes from Phase 2b, and the quoted summary gives no event rates. Treat it as a promising signal, not a settled fact.

Pfizer also reported that VESPER-3, a 64-week placebo-controlled study of weekly titration followed by monthly maintenance across four dose arms, is the one built around the monthly idea. The summary I could verify gives no weight-loss figures for it. So the monthly part, the part that makes berobenatide different, is the part with the least public data.

What Is Coming Next

Pfizer describes 10 ongoing and planned Phase 3 trials for berobenatide, per PharmExec and BioSpace. They cover chronic weight management and obesity-related conditions such as knee osteoarthritis and obstructive sleep apnea.

From the release as reported by MarketScreener:

  • VESPER-4 and VESPER-5 are ongoing pivotal studies of once-weekly dosing, in people without and with type 2 diabetes.
  • VESPER-6 is a pivotal Phase 3 study of once-monthly maintenance dosing, now open for enrollment.

Notice what is missing: a filing date. None of the sources I fetched gave a regulatory submission timeline, and I am not going to guess one. The deal funds development through 2028, which tells you the work is long, but it is not a launch date.

How This Fits With the Compounds We Already Profile

Berobenatide is not in our database yet, and it is not an approved drug. Here is how to place it among the GLP-1 family people are actually researching:

The honest takeaway: berobenatide is one more entrant in a crowded pipeline, with encouraging early data and a long road left. The monthly angle is real convenience if it holds up. Whether it holds up is exactly what the Phase 3 program is for.

Our Take

Big pharma is spending billions, and bringing in outside investors, to chase the same goal the research community has been poking at for years: better, more tolerable, less frequent GLP-1 signaling. The cost of that process shows up later, in the price of whatever reaches the market.

For now, treat this as a "watch" item. The funding is confirmed. The early efficacy number is real but exploratory. The monthly data is thin in public. Read the primary releases, check the caveats, and ignore anyone who treats a Phase 2b extension as a finished product.

This article is educational, not medical advice.

Sources

Researching peptides? Track your protocols free.

Pro members save 10% on every shop order, all year, with no cap.

See Pro Benefits

Topics covered:

berobenatidePfizerGLP-1monthly GLP-1obesityclinical trials

Enjoyed this article?

Get an email when we publish a new guide, when something sold out is back, or when a price drops.